The Australian Cancer Research Foundation is governed by an honorary Board of Trustees. The Board consists of 10 dedicated professionals and philanthropists. It steers the Foundation’s strategic direction to ensure all funds raised by our supporters are used in the best possible way to help outsmart cancer.
MR TOM S DERY AO
BCom (Econ) (University of NSW); MBA (Stanford). ACRF Director since April 1994, Chairman since 1999. Chairman M & C Saatchi. Chairman of AIME. Chairman of Queenwood School for Girls. Senate Committee Member of University of Sydney (Strategy Oversight and Risk).
MR GREG J CAMM
MBA (University of Melbourne), BBus (Monash), CPA, SF Fin, MAICD. ACRF Director since December 2000. Chairman of AMIST Super. Director of Bank Australia Ltd and SEDA Group Ltd.
MR RUSSELL R CAPLAN
LLB, FAICD, FAIM. ACRF Director since March 2011. Chairman of the Melbourne and Olympic Parks Trust and Horizon Roads Pty Ltd. Non-executive Director of Aurizon Holdings Limited. Director of St Kilda Football Club.
MR TIMOTHY B I CROMMELIN
B Comm (UQld), FSLE, FSIA, Advanced Management Program (University of Hawaii). ACRF Director since March 2000. Chairman of Morgans Holdings (Australia) Limited and AP Eagers Limited. Director of Senex Energy Limited. Member of the Senate for the University of Queensland.
MR STEPHEN GERLACH AM
ACRF Director since November 1996. Chancellor of Flinders University, Adelaide. Chairman of Adelaide Capital Partners Pty Ltd, Gerlach Asset Development Pty Ltd and Ebony Energy Ltd. Trustee of Psychosis Australia Trust. Director of Beston Pacific Asset Management Pty Ltd Group, Beston Global Foods Ltd and The General Sir John Monash Foundation Ltd. Member of AICD Corporate Governance Committee.
MS JENNIFER HEWETT
ACRF Director since September 2012. National Affairs Columnist at the Australian Financial Review.
AIR CHIEF MARSHAL SIR ANGUS HOUSTON AK AFC (Ret’d)
ACRF Director since November 2011. Chancellor of University of the Sunshine Coast. Chairman of Air Services Australia; Defence South Australia Advisory Board; Canberra Symphony Orchestra; University of New South Wales Canberra Advisory Council and Victoria Police Corporate Advisory Board. Board Member of the Lowy Institute; Thompson Institute Pty Ltd; Australian Federal Police Corporate Advisory Board; Victoria Police Executive Command Committee; Greater Good Canberra and ANZAC Centenary Public Fund Board. Consultant for Ernst and Young and Special Adviser to the Minister for Veterans’ Affairs on the ANZAC Centenary. Special Envoy for Trade and Investment South Australia Government. Visiting Fellow of Australian National University – National Security College. Patron of Sunnyfield Independence; Stand tall for PTSD, Australian American Association (Canberra Division); Bravery Trust; Bomber Command; Glycomics Childhood Leukaemia; ShelterBox Australia; Snowy Hydro South Care Rescue; European Alliance Against Depression Australian Chapter (WA); The Centenary of ANZAC Centre; Tropical Brain and Mind Research Foundation and Painaustralia. Ambassador for Soldier On.
MR PETER JONES
LLB, (University of Technology, Sydney). BSurv, (University of NSW). ACRF Director since June 2005. Deputy General Counsel at the Reserve Bank Australia.
MR SIMON J PERROT
BSc, (UMelb). MBA, Australian Graduate School of Management. ACRF Director since December 2000. Non-executive Director of Lend Lease Retirement Benefit Fund and Lend Lease Real Estate Investments Limited. Director of Wayside Chapel.
MR STEPHEN R RIX
BEc, CA, FAICD. ACRF Director since December 2005. Chairman of Travelex Asia-Pacific and Bennelong Funds Management Group Ltd. Director of Allen & Unwin Pty Limited and Nightingale Partners Pty Ltd.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.